Stan in The Globe & Mail

Stan Wong’s Top Three Stock Picks

September 18, 2015

Celgene is a biopharmaceutical company focusing on the discovery, development and commercialization of therapies designed to treat cancer and other severe, immune, inflammatory conditions. CELG continues to have strong growth prospects and will benefit from aging demographics longer-term. CELG’s therapy pipeline is very robust allowing for further diversification of its revenue stream over the next several years. The shares are compelling, trading at a 23x forward price-earnings multiple with a long-term projected earnings per share (EPS) compound annual earnings growth rate (CAGR) of about 25 per cent.

View Full Article